JP2021521439A - がん血清バイオマーカーおよびその使用方法 - Google Patents

がん血清バイオマーカーおよびその使用方法 Download PDF

Info

Publication number
JP2021521439A
JP2021521439A JP2020555862A JP2020555862A JP2021521439A JP 2021521439 A JP2021521439 A JP 2021521439A JP 2020555862 A JP2020555862 A JP 2020555862A JP 2020555862 A JP2020555862 A JP 2020555862A JP 2021521439 A JP2021521439 A JP 2021521439A
Authority
JP
Japan
Prior art keywords
cancer
cytokine
patient
biomarker
biomarkers
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2020555862A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021521439A5 (https=
JPWO2019200223A5 (https=
Inventor
ヤン ワン，
ヤン ワン，
サイモン ポール フリッカー，
サイモン ポール フリッカー，
カム マリー スプロット，
カム マリー スプロット，
Original Assignee
エックス４ ファーマシューティカルズ， インコーポレイテッド
エックス４ ファーマシューティカルズ， インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by エックス４ ファーマシューティカルズ， インコーポレイテッド, エックス４ ファーマシューティカルズ， インコーポレイテッド filed Critical エックス４ ファーマシューティカルズ， インコーポレイテッド
Publication of JP2021521439A publication Critical patent/JP2021521439A/ja
Publication of JP2021521439A5 publication Critical patent/JP2021521439A5/ja
Publication of JPWO2019200223A5 publication Critical patent/JPWO2019200223A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5082—Supracellular entities, e.g. tissue, organisms
    • G01N33/5088—Supracellular entities, e.g. tissue, organisms of vertebrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5751—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the skin, e.g. melanoma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57525—Immunoassay; Biospecific binding assay; Materials therefor for cancer of the liver or pancreas
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/521—Chemokines
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/52—Assays involving cytokines
    • G01N2333/555—Interferons [IFN]
    • G01N2333/57—IFN-gamma
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Gastroenterology & Hepatology (AREA)
JP2020555862A 2018-04-13 2019-04-12 がん血清バイオマーカーおよびその使用方法 Pending JP2021521439A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201862657370P 2018-04-13 2018-04-13
US62/657,370 2018-04-13
US201862734133P 2018-09-20 2018-09-20
US62/734,133 2018-09-20
US201862756496P 2018-11-06 2018-11-06
US62/756,496 2018-11-06
PCT/US2019/027169 WO2019200223A1 (en) 2018-04-13 2019-04-12 Cancer serum biomarkers and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2021521439A true JP2021521439A (ja) 2021-08-26
JP2021521439A5 JP2021521439A5 (https=) 2022-04-19
JPWO2019200223A5 JPWO2019200223A5 (https=) 2022-04-19

Family

ID=68164571

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020555862A Pending JP2021521439A (ja) 2018-04-13 2019-04-12 がん血清バイオマーカーおよびその使用方法

Country Status (6)

Country Link
US (1) US20210025895A1 (https=)
EP (1) EP3775877A4 (https=)
JP (1) JP2021521439A (https=)
CN (1) CN112005114A (https=)
CA (1) CA3095331A1 (https=)
WO (1) WO2019200223A1 (https=)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2017106332A1 (en) 2015-12-14 2017-06-22 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN109069426B (zh) 2015-12-14 2021-10-29 X4 制药有限公司 治疗癌症的方法
PL3393468T3 (pl) 2015-12-22 2023-01-23 X4 Pharmaceuticals, Inc. Metody leczenia niedoboru odporności
US11337969B2 (en) 2016-04-08 2022-05-24 X4 Pharmaceuticals, Inc. Methods for treating cancer
CN109640988A (zh) 2016-06-21 2019-04-16 X4 制药有限公司 Cxcr4抑制剂及其用途
WO2017223243A1 (en) 2016-06-21 2017-12-28 X4 Pharmaceuticals, Inc. Cxcr4 inhibitors and uses thereof
ES2870920T3 (es) 2016-06-21 2021-10-28 X4 Pharmaceuticals Inc Inhibidores de CXCR4 y usos de los mismos
CN112771177A (zh) * 2018-05-21 2021-05-07 纳米线科技公司 分子基因标签及其使用方法
US10548889B1 (en) 2018-08-31 2020-02-04 X4 Pharmaceuticals, Inc. Compositions of CXCR4 inhibitors and methods of preparation and use
CA3171250A1 (en) 2020-03-10 2021-09-16 E. Lynne KELLEY Methods for treating neutropenia
WO2021263115A1 (en) * 2020-06-26 2021-12-30 Icahn School Of Medicine At Mount Sinai Compositions and methods for treating cancer, overcoming pd-1/pd-l1 blockade resistance, and determining resistance to checkpoint inhibitor treatment
AU2021409465A1 (en) 2020-12-21 2023-08-03 Freenome Holdings, Inc. Markers for the early detection of colon cell proliferative disorders
US12523658B2 (en) * 2021-08-27 2026-01-13 The Board Of Regents Of The University Of Texas System Methods for the assessment of risk and treatments for liver cancers and lethal liver disease complications
CA3233049A1 (en) * 2021-09-20 2023-03-23 Droplet Biosciences, Inc. Lymphatic fluid for diagnostics
CN114859050B (zh) * 2022-05-30 2026-02-17 复旦大学附属肿瘤医院 三阴性乳腺癌免疫治疗疗效预测标志物ccl19的检测方法

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004523920A (ja) * 2001-03-19 2004-08-05 ハリス　コーポレイション 冷却基板を有する電子装置及びその方法
WO2013017562A1 (en) * 2011-07-29 2013-02-07 Pierre Fabre Medicament Use of the antibody i-3859 for the detection and diagnosis of cancer
WO2016168133A1 (en) * 2015-04-17 2016-10-20 Merck Sharp & Dohme Corp. Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
WO2017127811A1 (en) * 2016-01-22 2017-07-27 X4 Pharmaceuticals, Inc. Methods for treating cancer
JP2018505658A (ja) * 2014-12-09 2018-03-01 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｐｄ−１アンタゴニストに対する応答の遺伝子シグネチャーバイオマーカーを得るための系および方法
JP2019510785A (ja) * 2016-04-08 2019-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド 癌を処置する方法

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2004523920A (ja) * 2001-03-19 2004-08-05 ハリス　コーポレイション 冷却基板を有する電子装置及びその方法
WO2013017562A1 (en) * 2011-07-29 2013-02-07 Pierre Fabre Medicament Use of the antibody i-3859 for the detection and diagnosis of cancer
JP2018505658A (ja) * 2014-12-09 2018-03-01 メルク・シャープ・アンド・ドーム・コーポレーションＭｅｒｃｋ Ｓｈａｒｐ ＆ Ｄｏｈｍｅ Ｃｏｒｐ． Ｐｄ−１アンタゴニストに対する応答の遺伝子シグネチャーバイオマーカーを得るための系および方法
WO2016168133A1 (en) * 2015-04-17 2016-10-20 Merck Sharp & Dohme Corp. Blood-based biomarkers of tumor sensitivity to pd-1 antagonists
WO2017127811A1 (en) * 2016-01-22 2017-07-27 X4 Pharmaceuticals, Inc. Methods for treating cancer
JP2019510785A (ja) * 2016-04-08 2019-04-18 エックス４ ファーマシューティカルズ， インコーポレイテッド 癌を処置する方法

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
BURLES A. JOHNSON III: "Strategies for Increasing Pancreatic Tumor Immunogenicity", CLIN CANCER RES, vol. 23, no. 7, JPN6023008959, 2017, pages 1656 - 1669, ISSN: 0005004665 *
EFIMIA BOUTSIKOU: "Tumour necrosis factor, interferon-gamma and interleukins as predictive markers of antiprogrammed ce", THER ADV MED ONCOL, vol. 10, JPN6023008968, 2018, pages 1 - 8, ISSN: 0005004662 *
M. F. SANMAMED: "Changes in serum interleukin-8 (IL-8) levels reflect and predict response to anti-PD-1 treatment in", ANNALS OF ONCOLOGY, vol. 28, JPN6023008967, 2017, pages 1988 - 1995, ISSN: 0005004661 *
MIGUEL F. SANMAMED: "Serum Interleukin-8 Reflects Tumor Burden and Treatment Response across Malignancies of Multiple Tis", CLIN CANCER RES, vol. 22, no. 22, JPN6023008969, 2014, pages 5697 - 5707, ISSN: 0005004663 *
NAOYA YAMAZAKI: "Cytokine biomarkers to predict antitumor responses to nivolumab suggested in a phase 2 study for adv", CANCER SCI, vol. 108, JPN6023008966, 2017, pages 1022 - 1031, ISSN: 0005004660 *
NATIONAL HARBOR: "31st Annual Meeting and Associated Programs of the Society for Immunotherapy of Cancer (SITC 2016):", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 4(Suppl 1), JPN6023009945, 2016, pages 82, ISSN: 0005004664 *
ROBSRT H.I. ANTDTBACKA, X4P-001, AN ORALLY BIOAVAILABLE CXCR4 ANTAGONIST, INCREASES T CELL INFILTRATION IN HUMAN METASTATIC, JPN6023008965, November 2017 (2017-11-01), ISSN: 0005004659 *

Also Published As

Publication number Publication date
EP3775877A4 (en) 2021-12-22
EP3775877A1 (en) 2021-02-17
WO2019200223A1 (en) 2019-10-17
CA3095331A1 (en) 2019-10-17
CN112005114A (zh) 2020-11-27
US20210025895A1 (en) 2021-01-28

Similar Documents

Publication Publication Date Title
JP2021521439A (ja) がん血清バイオマーカーおよびその使用方法
JP7343565B2 (ja) 正規化バイオマーカースコアからがん治療を特定するためのシステム及び方法
Kroemer et al. Immunosurveillance in clinical cancer management
US20210349099A1 (en) Cancer biomarkers and methods of use thereof
Lambert et al. Association of baseline and pharmacodynamic biomarkers with outcomes in patients treated with the PD-1 inhibitor budigalimab
CN115667552A (zh) 与对局部晚期或转移性尿路上皮癌中的免疫疗法敏感性相关的肿瘤突变负荷
HK40017854A (en) Systems and methods for identifying cancer treatments from normalized biomarker scores
HK40017854B (en) Systems and methods for identifying cancer treatments from normalized biomarker scores

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220411

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20220411

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20230224

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20230306

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20231017